According to the Digestive Diseases Research Institute (DDRI) of Tehran University of Medical Sciences (TUMS) , despite only four months from the publication of the results from “Polypill” by Iranian researchers in the journal of The Lancet (August 24, 2019), data from PlumX Metrics database shows the astounding attention of social media users around the world to its outcomes.
The study, directed by professor Reza Malekzadeh the lead investigator of the Golestan Cohort Study – was conducted in collaboration with researchers from Medical Universities of Tehran, Golestan, Isfahan and international research institutes in the United Kingdom (Birmingham University) and the United States; and published as an article titled “Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial ".
The findings of this study showed that the regular and continuous use of Polypill tablets reduced mortality from cardiovascular diseases, heart attacks and strokes by more than 50 percent.
According to the PlumX Metrics analysis, in 2019, the PolyPill article exceeded 89% of articles published in The Lancet Journal according to the Usage Metrics, 90% based on the Captures Metrics, 92% by the Citations Metrics, 97% in Social Media Metrics, and 99% by the Mentions Metrics.
These results come as the Polypill article is more recent compared to other articles published in The Lancet in 2019, and despite a shorter time period from when it was published last year.
Based on the results of this analysis, from the time of its publication up until the end of 2019, the Polypill article has achieved a record of 170 in Usage, 70 in Captures, 9 in Citations, 66 in Mentions and 1,116 in Social Media Metrics.
Lancet's perspective of "PolyIran" : A study based on a robust research infrastructure
In a previous analysis of the “PolyIran” The Lancet had described it as an unprecedented effort by a research team towards better understanding of the value of “polypill” in the fight against premature deaths as a major global health problem, which was achievable based on a robust research infrastructure for the conduction of a long-term clinical trial.
The Lancet recognizes the findings of this study by Iranian researchers especially beneficial for middle- and low-income countries which bear 80 percent of the global burden for cardiovascular diseases, heart attacks and strokes; and useful for the prevention of cardiovascular and cerebrovascular events in other countries.
According to a report from the Digestive Disease Research Institute (DDRI) of Tehran University of Medical Sciences, the Polypill Study was carried out over a period of 5 years on approximately 7,000 individuals obove the age of 50 who took part in the Golestan Cohort study with 50,000 participants.
The polypill tablet prescribed in this study which was desined by professor Reza Malekzadeh's research team and produced by “Alborz Darou” in 2010, included a combination of aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg for those who experienced cough as a side effect of enalapril), atorvastatin 20 mg and hydrochlorothiazide 12 mg; all of which are among the most essential pharmacological agents used in the treatment of patients with cardiovascular disorders in order to control blood pressure, lipids and clots.
What the "PolyIran" study has pioneered in today’s world is featuring one of the longest and largest community-based clinical trials, which for the first time, through providing some of the strongest scientific evidence, has proven that the burden of cardiovascular disease will be significantly reduced by continued adherence of patients to using polypill.
This is confirmed by a 57% reduction of heart attacks and strokes in participants who had a 70% adherence rate to polypill consumption.